CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 56 enrolled
Drug / intervention
Von Willebrand Factor-Containing Productdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04053699
NCT04053699N/ACompleted
CompareCT.gov

A Prospective, Multicenter, Non-Interventional Study Evaluating the Bleeding Incidence in Patients With Von Willebrand Disease Undergoing On-Demand Treatment

Octapharma·observational·Posted Aug 12, 2019·Updated Dec 7, 2023

In Brief

An observational study evaluating Von Willebrand Factor-Containing Product for Von Willebrand Diseases. Completed, enrolled 56 participants across 15 sites in 8 countries.

Detailed Summary

The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months. The data obtained will be used as a basis for historical comparisons with the bleeding and treatment pattern obtained from a clinical study on the efficacy of prophylactic treatment with a VWF/FVIII concentrate.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsVon Willebrand Diseases
CountriesBelarus, Bulgaria, Croatia, Hungary, Lebanon, Russia, Ukraine, United States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedAug 12, 2019
Enrollment StartJun 25, 2019
Primary CompletionJan 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.9 years ago

Interventions

Von Willebrand Factor-Containing Productdrug

Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country